International Clinical Trial: LAG-3-Mediated Dynamic Regulatory Mechanisms and Targeted Therapy Study in Sepsis-Induced Immune Dysregulation

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120136) titled 'LAG-3-Mediated Dynamic Regulatory Mechanisms and Targeted Therapy Study in Sepsis-Induced Immune Dysregulation' on March 10.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: Fuzhou University Affiliated Provincial Hospital

Condition: Sepsis

Intervention: LAG-3 high-expression group:None

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-04-01

Target Sample Size: LAG-3 high-expression group:15;LAG-3 low-expression group:15;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=312411

Published by HT D...